


Elomotecan

Chemical Properties

CAS No. :	220998-10-7
Formula:	C ₂₉ H ₃₂ ClN ₃ O ₄
Molecular Weight:	522.04
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan is able to inhibit different types of tumors with better efficacy.
Targets(IC50)	Others,Topoisomerase
In vitro	METHODS: Elomotecan (BN 80927 free base) (1, 10, 50, 100 μM, 72 hours) was used to treat human tumor cell lines (HT29, SKOV-3, DU145 and MCF7), and the IC50 values of the cells were detected by WAT method. RESULTS The IC50 values of Elomotecan against human tumor cancer cells (HT29, SKOV-3, DU145 and MCF7) were (0.0066, 0.013, 0.003, 0.048 μM) respectively. [2]
In vivo	METHODS: Elomotecan (BN 80927 free base) was administered as a 30-minute intravenous infusion at doses ranging from 1.5 to 75 mg every 3 weeks, and plasma concentration data and adverse effects were modeled using a population approach. RESULTS Elomotecan showed linear pharmacokinetics, and clearance decreased with age; the model predicted that CL was 47% and 61% lower in 60-year-old and 80-year-old patients, respectively, compared with younger patients (30 years old); neutropenia represented a dose-limiting toxicity, with the maximum tolerated dose and recommended dose (RD) of 75 and 60 mg, respectively; elomotecan caused severe neutropenia, fatigue, nausea, and vomiting in 20%, 5%, 2%, and 2% of patients at the RD, respectively. [1]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9156 mL	9.5778 mL	19.1556 mL
5 mM	0.3831 mL	1.9156 mL	3.8311 mL
10 mM	0.1916 mL	0.9578 mL	1.9156 mL
50 mM	0.0383 mL	0.1916 mL	0.3831 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Trocóniz IF, et al. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2012 Aug;70(2):239-50.

Huchet M, et al. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. *Ann N Y Acad Sci.* 2000;922:303-5.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481